INTRODUCTION AND OBJECTIVES:
Immune targeted therapy of nitric oxide synthases are being considered as a potential frontline therapeutics to treat patients diagnosed with locally advanced and metastatic prostate cancer. However, the role of nitric oxide (NO) in castration resistance prostate cancer (CPRC) is controversial because NO can increase nitrosative stress while simultaneously possessing anti-inflammatory properties. Accordingly, we tested the hypothesis that increased NO will lead to tumor suppression of CRPC through tumor micro environment.
METHODS: S-Nitrosoglutathione (GSNO), an active NO donor, is a potent therapeutic agent that has been safely used in human clinical trials for pre-eclampsia and persistent pulmonary hypertension. We treated CRPC murine models and 22Rv1 cells with GSNO and studied effects of increased NO levels, mechanism of action and its long term efficacy. Animal experiments were carried out in compliance with the Institutional Animal Care and Use Committee of University of Miami. Molecular analyses were performed using standard procedures.
RESULTS: S-nitrosoglutathione (GSNO), an NO donor decreased the tumor burden in murine model of CRPC by targeting tumors in a cell non autonomous manner. GSNO inhibited both the abundance of anti-inflammatory (M2) macrophages and expression of pERK indicating that tumor associated macrophages activity is influenced by NO. Additionally GSNO decreased IL-34 indicating suppression of tumor associated macrophage differentiation. Cytokine profiling of CRPC tumor grafts exposed to GSNO revealed a significant decrease in expression of G-CSF and M-CSF as compared to grafts not exposed to GSNO. We verified the durability of NO on CRPC tumor suppression by using secondary xenograft murine models.
CONCLUSIONS: This study validates the significance of NO on inhibition of CRPC tumors through TME. These findings may facilitate the development of previously unidentified NO-based therapy for CRPC. 
MP81-05 CRISPR SCREENING REVEALS GENES DRIVING RESISTANCE AND SENSITIVITY TO PARP INHIBITOR IN PROSTATE CANCER CELLS
Tomoaki Takai*, Xiao Bai, Takuya Tsujino, Adam Kibel, Li Jia, Boston, MA INTRODUCTION AND OBJECTIVES: While next-generation anti-androgens have been developed, castration-resistant prostate cancer (CRPC) remains a lethal disease. There is an urgent need for new therapeutic options in advanced PCa. Inhibitors of poly (ADPribose) polymerase (PARP) are a new type of targeted therapy, which works by preventing the enzyme PARP from DNA damage site in tumor cells. Cancer cells lacking BRCA1 or BRCA2 are hypersensitive to PARP inhibitor. A recent clinical trial has shown promising results of the PARP inhibitor olaparib in metastatic CRPC patients who have DNA-repair defects. However, one of the major barriers to effective treatment in clinical trials is how to select patients who most likely benefit from the treatment. Resistance to PARP inhibitor represents a formidable clinical problem. Identification of synthetic lethality is critical to address the emergence of drugresistant cancer. To this end, we perform a genome-wide CRISPR screen to determine the mechanisms of olaparib resistance and sensitivity in PCa cells. Our research goal is to identify candidate genes as potential biomarkers for drug response and resistance.
METHODS: We performed a genome-wide CRISPR screen in PCa LNCaP and C4-2B cells using a pooled CRISPR library that targets about 18,000 genes with 10 single guide RNAs (sgRNAs) for each gene. Infected cells were treated with olaparib or DMSO for 30 days (10 passages), and collected for next-generation sequencing. The enrichment of sgRNA in olaparib-treated cells was calculated using MAGeCK pipeline by comparing to DMSO-treated cells and cells prior to treatment. Positive selection (enriched sgRNAs) identifies gene knockouts that result in resistance to olaparib. Negative selection (depleted sgRNAs), on the other hand, identifies gene knockouts that increase olaparib sensitivity.
RESULTS: We detected more than a hundred candidate genes from both positive and negative selection. As expected, genes from negative selection are highly enriched for DNA repair pathways, including well-known BRCA1 and ATM. We have further validated a subset of novel DNA repair genes through generating knockout cell lines and testing their response to olaparib. We also identified a number of genes from the positive selection, knockout of which led to PCa cell resistance to olaparib. These genes include PARP1, PARP2 and PARG, which represent novel PARP inhibitor resistance mechanisms.
CONCLUSIONS: We have demonstrated the power of CRISPR screening for identification of novel genes as potential biomarkers of olaparib resistance and sensitivity in PCa.
Source of Funding: none

MP81-06 OVERCOMING CABAZITAXEL RESISTANCE BY G2/M REGULATING GENES IN CASTRATION-RESISTANT PROSTATE CANCER
Hiroshi Hongo*, Takeo Kosaka, Yoshinori Yanai, Yota Yasumizu, Yasumasa Miyazaki, Nobuyuki Tanaka, Kazuhiro Matsumoto, Ryuichi Mizuno, Eiji Kikuchi, Mototsugu Oya, Shinjuku-ku, Japan INTRODUCTION AND OBJECTIVES: Recently, cabazitaxel (CBZ) was identified as the most effective cytotoxic agent to demonstrate an improvement in survival in men with docetaxel-refractory castration-resistant prostate cancer (CRPC). However, the survival benefit of CBZ for CRPC patients is limited to only a few months. Because CBZ-resistant CRPC has an extremely poor prognosis, establishment of a novel treatment for CBZ-resistant CRPC is greatly needed. The aim of this study was to explore drugs targeting the CBZ-resistance related genetic network by bioinformatic analysis and testing the antitumor effects of CBZ for resistant CRPC.
METHODS: Two CRPC cell lines, DU145 and PC3, and two CBZ-resistant cell lines were used in this study. We performed screening tests for candidate drugs to inhibit the genetic network in CBZ-resistant CRPC using in silico analysis, and identified a candidate drug, KHO931 (Figure) . The antitumor effect of KHO931 for CBZ-resistant cell lines was determined using mice xenograft tumor models.
RESULTS: We incubated DU145 and PC3CR cells with gradually increasing concentrations of CBZ for 2 years and established the CBZ-resistant cell lines, DU145CR and PC3CR. We compared the cytotoxic effect of CBZ on DU145, PC3, DU145CR and PC3CR cells using a cell viability assay. The half maximal inhibitory concentration (IC50) of CBZ in CBZ-resistant cell lines was 3 times higher than that for parental cells. Cell cycle analysis demonstrated DU145CR and PC3CR had resistance to G2/M arrest induced by CBZ. Microarray analysis revealed gene clusters related to cell division were upregulated in DU145CR and PC3CR. Next, we tested the anti-tumor effect of the candidate drug KHO931 for overcoming CBZ-resistance.
